Michael N. Dudley

Michael N. Dudley publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Michael N. Dudley sits on this spectrum.

Michael N. Dudley D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Michael N. Dudley sits on this spectrum.

Best Publications

• Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

  Johan W. Mouton;Michael N. Dudley;Otto Cars;Hartmut Derendorf

  645
  Citations

• Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

  Hecker Sj;Reddy Kr;Totrov M;Hirst Gc

  428
  Citations

• Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

  Richard G. Wunderink;Evangelos J. Giamarellos-Bourboulis;Galia Rahav;Amy J. Mathers

  416
  Citations

• Framework for optimisation of the clinical use of colistin and polymyxin B : the Prato polymyxin consensus

  Roger Leigh Nation;Jian Li;Otto Cars;William Couet

  399
  Citations

• Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

  Olga Lomovskaya;Dongxu Sun;Debora Rubio-Aparicio;Kirk Nelson

  394
  Citations

• Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

  Keith S. Kaye;Tanaya Bhowmick;Symeon Metallidis;Susan C. Bleasdale

  352
  Citations

• Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

  Nelson Jumbe;Arnold Louie;Robert Leary;Weiguo Liu

  324
  Citations

• Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole

  Adriana M. Nascimento;Gustavo H. Goldman;Steven Park;Salvatore A. E. Marras

  314
  Citations

• 2′,3′-Didehydro-3′-deoxythymidine (d4T) in Patients with AIDS or AIDS-Related Complex: A Phase I Trial

  Marcia J. Browne;Kenneth H. Mayer;Stephanie B. D. Chafee;Michael N. Dudley

  240
  Citations

• Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

  Unknown

  234
  Citations

• Discovery of Cyclic Boronic Acid QPX7728, an Ultra-broad-spectrum Inhibitor of Serine and Metallo Beta-lactamases.

  Scott J. Hecker;K. Raja Reddy;Olga Lomovskaya;David C. Griffith

  218
  Citations

• Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.

  Dongxu Sun;Debora Rubio-Aparicio;Kirk Nelson;Michael N. Dudley

  189
  Citations

• Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial.

  Michael N. Dudley;James C. McLaughlin;George Carrington;Jean Frick

  186
  Citations

• Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

  Michael N Dudley;Paul G Ambrose;Sujata M Bhavnani;William A Craig

  183
  Citations

• A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens

  Unknown

  183
  Citations

• Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones.

  Unknown

  172
  Citations

• Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.

  Johan W Mouton;Michael N Dudley;Otto Cars;Hartmut Derendorf

  153
  Citations

• Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation.

  John S Bradley;Michael N Dudley;George L Drusano

  151
  Citations

• In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

  Meredith A. Hackel;Olga Lomovskaya;Michael N. Dudley;James A. Karlowsky

  149
  Citations

• Interactions of Fluoroquinolones with Other Drugs: Mechanisms, Variability, Clinical Significance, and Management

  Unknown

  144
  Citations